Key Clinical Trials in Pharmacological Treatment of Early Parkinson’s Disease

Key Clinical Trials in Pharmacological Treatment of Early Parkinson’s Disease

US Neurology, 2009;5(1):25-9

dots

Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disease and affects more than one million people in the US. The management of PD involves treatment of motor and non-motor symptoms of the disease. The armamentarium of treatment options for PD has increased substantially over the last 10 years. This article reviews recent clinical trials investigating efficacy, complications of treatment, and possible neuroprotective agents in patients with early PD.

Keywords
Parkinson’s disease, treatment, neuroprotection, levodopa, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors

Disclosure: Binit Shah, MD, has no conflicts of interest to declare. Tanya Simuni, MD, is a current or former consultant and has received honoraria from TEVA, Boehringer Ingelheim, GSK, Novartis, and UCB Pharma.
Received: January 19, 2009 Accepted: August 28, 2009
Correspondence: Tanya Simuni, MD, Associate Professor of Neurology, and Director, Parkinson’s Disease and Movement Disorders Center, Northwestern University, 710 North Lake Shore Drive, 1126, Chicago, IL 60611. E: tsimuni@nmff.org

Parkinson’s disease (PD) is the second most common neurodegenerative disease and affects more than one million people in the US.1 The cause of PD is unknown, but it involves the loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain. Clinically, PD is characterized by the triad of rigidity, bradykinesia, and rest tremor, and is often associated with postural instability. While motor disability is the hallmark of PD, there is a whole spectrum of non-motor manifestations that can significantly contribute to the disease-related disability.

There are two commonly used scales to measure PD-related disability and severity of the disease. The Hoehn and Yahr Scale is a measure of overall severity of PD, with a score of zero indicating no disease and a score of five indicating end-stage disease.2 The Unified Parkinson’s Disease Rating Scale (UPDRS) consists of four parts.3,4 Part I is a brief evaluation of mentation, behavior, and mood; part II assesses activities of daily living (ADL); part III is objective assessment of motor disability; and part IV is assessment of complications of therapy (i.e. dyskinesia and motor fluctuations).

To read full article please click here

Keywords:
Parkinson’s disease, treatment, neuroprotection, levodopa, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, parkinson's disease levodopa, parkinson's disease neurological, diagnosis parkinson's disease, parkinson's disease deep brain stimulation, parkinson's disease symptoms, parkinson's disease tremor,

Copyright® 2012 Touch Group PLC. All rights reserved.
Touch Neurology is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendations.